Insurance giant LIC and healthcare provider Max Healthcare experienced significant shifts on Monday, ranking among the top performers in India's stock market. These movements indicate increased investor interest in these two companies.

CLSA recommends buying Max Health stocks, predicting a price of ₹1,210. However, potential margin pressure in the growth from bed days could stem from decreased demand for oncology drugs.

Max Healthcare's Q4 performance has led to differing opinions among brokerages, with some attributing growth to increased volumes. Analysts' target prices indicate varied expectations for the stock's future trajectory.

Goldman Sachs maintains a positive outlook for Max Healthcare, adjusting their price forecast to ₹1,250, down from the previous ₹1,300.

Ganesh Dongre suggests considering investments in Hindustan Zinc, Max Healthcare, and HDFC Bank with set price goals. The Nifty index hovers between 23,300 and 24,000, but geopolitical tensions and recent US-Iran developments could influence market mood.

Max Health's stock plummets 6%, reflecting Q4 performance issues. ITC faces a 2% drop due to concerns over cigarette volume. Maruti shares slide following the announcement of a potential price hike worth up to ₹30,000 by June 2026.

Max Healthcare has announced a major investment of approximately 1,400 crores to establish a new 712-bed facility in Lucknow, indicating the company's commitment to expanding its healthcare services in the region. This marks an exciting step forward for the organization's growth plans.

The Competition Commission of India (CCI) has exonerated Max Healthcare from accusations of misusing its dominance related to the pricing of medicines in Delhi, avoiding any fines or adverse actions.

Max Health saw a 7.3% increase in Q4 net profit, reaching ₹342.2 crore, and revenue growth of 12.2%, totaling ₹2,143 crore. Notably, EBITDA increased by 18.6%, boosted by improved margins to 28.3%. Year-over-year progress indeed!

Max Healthcare achieved a significant 16% revenue increase in their recent fiscal year (FY26), signaling strong performance. They are now aiming to expand further, indicating continued growth and development.

Max Healthcare's strong revenue and profit growth might be countered by increased margin pressure in the upcoming fourth-quarter report, as suggested by analyst Meryldsouza.

Today, Sun Pharma, Hindalco, Eicher Motors, Torrent Pharma, and NTPC Green are set to release their Q4 results, with ITC, LIC, GAIL, Emami, Max Health, JSW Cement, Va Tech, and 3M India also under the spotlight for their financial performances. Investors will closely monitor these companies' results to gauge their performance in the recent quarter.

Max Healthcare has announced the approval of Q4 FY26 results, along with a 20% final dividend, and plans for a new 712-bed hospital in Lucknow. Notably, office relocation to Haryana, cost auditor reappointment, and promoter reclassification are currently under review.

Max Healthcare's shares experienced a 7% decline following disappointing Q4 results, with revenue at ₹2,541 crore falling short of expectations and margins dipping to 26.8%. The oncology segment saw a decrease in market share, and the company also faced closure of antitrust cases related to 12 hospitals by the Competition Commission of India over a decade-long period.

Max Healthcare is planning to increase its bed capacity by 3,500 over the next three years, as revealed in a recent discussion. This growth strategy is aimed at enhancing healthcare facilities and accommodating more patients.

Max Healthcare experienced a significant block trade on the NSE, with approximately 320 thousand shares traded at a price of Rs. 1026.5, resulting in a value of over 32.88 crores.

Max Healthcare's new Gurgaon hospital is projected to reach profitability by fiscal year 2028, with an emphasis on expanding the outpatient department and increasing overall capacity.

Max Health is gradually increasing bed capacity and aims to reach a quarter of sales from oncology, as Dwarka Hospital growth meets expectations. Occupancy at Noida facility has reached 65%, with Kalinga Hospital in Bhubaneswar achieving an annual EBITDA of INR 10 crores.

The Competition Commission of India (CCI) has finally settled a decade-long antitrust case implicating 12 hospitals, including Max Healthcare. Max Healthcare officially confirmed the resolution of competition-related charges leveled against them by CCI.

Max Healthcare has disclosed its Q4 earnings, highlighting essential financial figures for investors' review.

Max Healthcare is under scrutiny due to allegations of mismanagement and oppression after a significant stake acquisition in its subsidiary. The National Company Law Tribunal (NCLT) has scheduled a hearing for July 7, 2026, to address these concerns.

Max Healthcare's annual earnings per share (EPS) increased by 13%, with revenue reaching ₹81 billion in the last year, marking a 24% growth. The company's insiders hold a substantial ₹245 billion stake, ensuring their interests align with those of shareholders and potentially boosting future growth prospects.

Max Healthcare has taken over a 58.3% share in Kalinga Hospital for approximately INR 298 crore, transforming Kalinga into a subsidiary of Max Healthcare following a secured term loan financing.

Analysts suggest investing in NMDC, Zydus Lifesciences, Varun Beverages, Max Healthcare, and Tata Steel by May 15, 2026, with estimated prices of Rs 98 for NMDC, Rs 1,070 for Zydus, Rs 534 for Varun Beverages, Rs 1,101 for Max Healthcare, and Rs 240 for Tata Steel.

Max Healthcare will gather on May 21, 2026, to discuss and potentially approve their Q4 and full-year 2026 financial results. Additionally, the board is looking into proposing a final dividend for shareholders. Trading activities remain temporarily halted.

Max Healthcare has announced a change in categorization, with Radiant Life Care Hospital Foundation moving from Promoter Group to Public. This shift is due to promoter share sales and does not affect Max Healthcare's overall shareholding.

Max Healthcare's addition to the Nifty 50 index underlines its substantial influence in the market, despite having a relatively high P/E ratio of 67.5 compared to the industry average of 61.8, possibly hinting at ongoing optimism towards this sector.

Under IHH's restructuring since FY19, Fortis Healthcare significantly improved its governance and operations, achieving a robust 33% EBITDA CAGR (FY18-26E). Valued on a SoTP basis, their hospital business is priced at 30x and diagnostics at 23x EV/EBITDA, matching industry peers Max Healthcare and Apollo Hospitals' valuations.

Max Healthcare successfully resolved a ₹55.2 crore GST dispute, withdrawing the demand following a rectification order. The company is also set to acquire a 58.4% stake in Kalinga Hospital for ₹300 crores, further expanding its healthcare network.

Max Healthcare successfully had a Rs 55.2 crore GST demand withdrawn, indicating a positive resolution to the issue. This development does not seem to have any reported negative implications for the company's management or promoters.

Max Healthcare's outlook remains positive according to HSBC, who have maintained a 'Buy' rating and set a target price of ₹1,125. The decision is based on steady performance in Q4FY26 and growth in elective procedures, with capital expenditure expansion, limited margin impact, and robust hospital operations also noted.

Max Healthcare aims for a significant expansion, aiming to add over 10,000 inpatient beds within the next two years, indicating an ambitious focus on hospital bed capacity increase.

Goldman Sachs recommends buying shares in Max Healthcare, setting the price target at ₹1,300. They remain optimistic about the company's prospects.

Analysts suggest focusing on stocks like BPCL, Tata Steel, SBI Life, GAIL, and Ambuja Cement in energy, cement, and insurance sectors due to their promising outlook. Additionally, 360One, Nuvama Wealth, Max Healthcare, and domestic cyclicals are favored for their resilience, market recovery potential, and strategic positioning.

Max Healthcare has agreed to acquire a controlling interest in Kalinga Hospital, expanding its network and enhancing healthcare services. This strategic move aims to strengthen Max's presence in Odisha.

Max Healthcare expands its presence by purchasing a significant stake (58.4%) in a Bhubaneswar hospital for approximately INR 300 crores, securing a director's role for the following three years from May 2026.

Max Healthcare has agreed to purchase a 58.39% share of Kalinga Hospital for approximately INR 300 crores, with additional funding coming from loans worth INR 100 crores and a $5M investment via ECBS.

Max Healthcare has agreed to purchase a 58.4% stake in Kalinga Hospital for approximately INR 300 crore, marking an expansion into Eastern India. This move will be funded by a loan of INR 100 crore for hospital renovations and an additional INR 300 crore through external borrowing.

Max Healthcare experienced a significant block deal on the NSE, worth approximately $130 million for over one million shares, priced at around Rs. 926.5 each.